Sugi Predict

Sugi Predict / Compounds / SCHEMBL14745271

SCHEMBL14745271

SCHEMBL14745271

CCc1c(-c2ccc3c(c2)cc(CN2CCN(C(C)C)CC2)n3C)[nH]c(=O)c(C(=O)O)c1O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.35
▸ TLR9 Q9NR96 2/20 0.35
▸ TLR8 Q9NR97 2/20 0.35
▸ TLR7 Q9NYK1 2/20 0.35
▸ TACR2 P21452 6/20 0.34
▸ TACR3 P29371 5/20 0.34
▸ OPRM1 P35372 3/20 0.34
▸ PARP1 P09874 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33
▸ GAA P10253 1/20 0.32
▸ WNT1 P04628 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ MCHR1 Q99705 1/20 0.31
▸ ALK Q9UM73 1/20 0.31
▸ TACR1 P25103 1/20 0.31
▸ NR1H4 Q96RI1 1/20 0.31
▸ BAZ2A Q9UIF9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17597902 0.99 FAAH (0.35) FAAHTLR9TLR8TLR7TACR2
Hydrochloric Acid SCHEMBL17597696 0.93 FAAH (0.33) FAAHTLR9TLR8TLR7TACR2
SCHEMBL14745070 0.91 FAAH (0.38) FAAHTLR9TLR8TLR7GAA
Hydrochloric Acid SCHEMBL17597442 0.91 FAAH (0.37) FAAHTLR9TLR8TLR7GAA
SCHEMBL14744908 0.91 MCHR1 (0.38) FAAHTLR9TLR8TLR7GAA
SCHEMBL14741232 0.91 MCHR1 (0.36) FAAHTLR9TLR8TLR7GAA
SCHEMBL14746156 0.90 MCHR1 (0.37) FAAHTLR9TLR8TLR7GAA
SCHEMBL14745224 0.89 FAAH (0.34) FAAHGAAWNT1DYRK1AMCHR1
SCHEMBL14744931 0.89 FAAH (0.40) FAAHTLR8TLR7PARP1PARP2
SCHEMBL14745492 0.89 FAAH (0.35) FAAHTACR2TACR3OPRM1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 — — US claimed
WO-2016039937-A1 BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 — — WO claimed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US claimed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 — — EP claimed
CN-103889224-A ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC 2014-06-25 — — CN claimed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 — — WO claimed
US-20230042198-A1 Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions LA JOLLA INST FOR IMMUNOLOGY (US) 2023-02-09 — — US disclosed
WO-2021108561-A1 METHODS AND COMPOSITIONS FOR MODULATING HETEROCHROMATIN DYSFUNCTION, GENOMIC INSTABILITY, AND ASSOCIATED CONDITIONS LA JOLLA INSTITUTE FOR IMMUNOLOGY (US) 2021-06-03 — — WO disclosed
US-10927160-B2 Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-23 — — US disclosed
US-20170320951-A1 METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) 2017-11-09 — — US disclosed
US-20170283481-A1 Engineered Invariant Natural Killer T (iNKT) Cells and Methods of Making and Using Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-10-05 — — US disclosed
EP-3164713-A1 METHODS FOR DIAGNOSING AND TREATING CD1D RESTRICTED GAMMA/DELTA T CELL LYMPHOMAS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2017-05-10 — — EP disclosed
US-9623083-B2 Method to screen for an activator of adipose-resident NK cells CORNELL UNIVERSITY (US) 2017-04-18 — — US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 — — US disclosed
US-20140193361-A1 SYSTEMIC GLUCOSE TOLERANCE IN TYPE-2 DIABETES CORNELL UNIVERSITY (US) 2014-07-10 — — US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 — — EP disclosed
WO-2013033283-A1 IMPROVING SYSTEMIC GLUCOSE TOLERANCE IN TYPE-2 DIABETES CORNELL UNIVERSITY (US) 2013-03-07 — — WO disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 — — WO disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP FAAH 4028/4885TLR9 392/4885TLR8 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.